Explority AI launches open drug discovery intelligence hub covering 5,846 rare diseases

Open-access AI hub helps pharma and biotech teams make confident R&D and business development decisions across rare diseases, saving weeks on research.



Explority AI launches drug discovery intelligence hub covering 5,846 rare diseases

NEW YORK, NY, UNITED STATES, September 10, 2026 / EINPresswire.com/ -- Explority AI, the company known for training large language models to advance drug discovery across rare diseases, opens an intelligence hub that closes the gap between academic research and the pharmaceutical industry in early-stage drug discovery.

Rare diseases affect more than 300 million people worldwide, yet the information needed to uncover and evaluate new drug opportunities is distributed across dozens of sources: prevalence figures in one registry, current treatments in several clinical guidelines, the competitive landscape scattered across multiple drug databases, and relevant research spread across thousands of published papers.

> Opening intelligence hub for rare disease means teams no longer have to rebuild drug discovery picture from scratch every time."
>
> *Andrew Obolenskiy, Co-founder and CEO, Explority AI*

The new open-access intelligence hub covers 5,846 rare diseases. Each disease page brings together scattered information on drug discovery into a single platform – covering population, burden, standard of care gaps, literature overview, live research and drug discovery landscapes for emerging orphan therapies.

For biotech and pharma teams, that consolidation means time saved and better-informed decisions at the riskiest, earliest stage of drug discovery. The Explority AI rare disease hub eliminates weeks of manual research and reduces the risk of decisions based on outdated or incomplete information. Each page is built and continuously updated using a corpus of more than 1 million scientific papers on drug discovery – the same corpus that powers the company's

models for forecasting the probability of success in clinical trials.

“Opening this directory means researchers, R&D and business development teams in pharma no longer have to rebuild that picture from scratch for every rare disease they investigate,” said Andrew Obolenskiy, Co-founder and CEO of Explority AI.

Why open access matters

Most tools built for pharmaceutical research charge for access to basic disease landscaping, which slows down the earliest and most information-heavy stages of drug discovery – exactly when researchers, patient advocates, and biotech companies most need a clear view of unmet need, existing and emerging opportunities. By making the directory freely available, Explority AI is aiming to accelerate drug discovery and drug repurposing for the rare diseases where new therapies could make the biggest difference.

How it works

The hub is organized as a single searchable directory. A user can explore any of the 5,846 rare diseases to view population and burden figures, standard-of-care gaps, the volume and pace of new research, and a comprehensive table of orphan drug designations associated with each disease. The underlying data updates continuously as new papers are published and new designations are granted, so the landscape stays current without manual tracking.

The directory sits alongside Explority AI's core product, which forecasts the probability of success for early-stage therapies across rare diseases. Based on published research, large language models rank which programs are most likely to succeed in trials – years before clinical signals emerge. The intelligence hub adds the broader context: how large the affected population is, how well it is currently served, how crowded or open the drug discovery landscape already is, what therapies succeeded in clinical trials and what failed.

Where it fits in pharma and biotech R&D

Orphan therapies now account for a majority of recent FDA approvals (54% in 2025) and generate returns above non-orphan drugs, which has pushed rare disease pipelines up the priority list for pharma companies, biotech developers, and life-science investors alike. Teams doing deal sourcing, in-licensing evaluation, or early-stage R&D planning can use the hub to screen diseases across all therapy types, including: small molecules, antibodies, therapeutic proteins, RNA therapies, gene and cell therapies.

About Explority AI

Explority AI Inc. is a U.S.-registered company based in New York. It trains large language models on drug discovery data to forecast which early-stage therapies are most likely to succeed in clinical trials, using published biomedical literature linked to real-world drug development outcomes. The platform serves pharma companies, biotechs, and bioVC funds with probability of success forecasts for early-stage therapies across rare diseases.

Explore the new intelligence hub for rare disease drug discovery.

Julia Mozyleva
Explority AI Inc.
media@explority.ai
Visit us on social media:
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/941205338

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.